Philippe Bégin , M.D. , FRCPC , Ph.D.
    Philippe Bégin
    Research Axis
    Immune Diseases and Cancer Axis
    Research Theme
    Immune diseases: mechanisms, new therapeutic approaches and disease outcomes


    • Associate Professor, Department of Medicine, Université de Montréal
      Director, Oral Immunotherapy Clinic (CITO), CHU Sainte-Justine
    • Immuno-Allergist, CHU Sainte-Justine
    • Researcher, CHU Sainte-Justine


    Groupe de Recherche sur les Allergies ALimentaires (GRAAL)

    • Philippe Bégin (Allergist, Director)
    • Anne Des Roches (Allergist)
    • Louis Paradis (Allergist)
    • Kathryn Saaman (Allergist)
    • Jonathan Lacombe Barrios (Allergist)
    • François Graham (Allergist)
    • Pauline Azzano (Research Fellow)
    • Alexandra Langlois (Research)
    • Stéphanie Pernice (Registered Dietician)
    • Véronique Bastien (Food Lab Technician)
    • Marie-Hélène Lavergne (Research Nurse)
    • Lucie Lavallée (Nurse-Clinician, OIT)
    • Isabelle Boisvert (Research Assistant)
    • Alain Maurice (Research Assistant)
    • Nadia Martineau (technical Assisant)
    • Caroline Dion (technical Assistant)
    • Hélène Leroux (Graduate Student)
    • Élise Dufresne (Graduate Ttudent)
    • Yosra Benachi (Administrative Agent)


    • PhD in Biomedical Sciences, Université de Montréal, 2015
    • Research Fellowship on Oral Immunotherapy, Visiting Scholar, Stanford University, 2014
    • Allergy and Clinical Immunology Specialty Diploma, Université de Montréal, 2012
    • Internal Medicine Specialty Diploma, Université de Montréal, 2011
    • MSc in Biomedical Sciences, Université de Montréal, 2008
    • Doctorate in Medecine (MD), Université de Montréal, 2007

    Research Topics

    • Clinical trials
    • Evaluative research
    • Participative research
    • Healthcare organization
    • Food allergies
    • Allergic asthma
    • Anaphylaxis
    • Oral immunotherapy

    Career Summary

    Following complementary research training on oral immunotherapy at Stanford University in California, Dr Philippe Bégin was recruited as active researcher at the CHU Sainte-Jusine, where he established a research program in allergy healthcare delivery. In collaboration with patient groups, with the CHU Sainte-Justine Foundation and with the Ministry of Health and Social Services of the province, he initiated a pilot project for a public clinical offer in oral immunotherapy dedicated to patients suffering from severe food allergies. His research program combines clinical trials with evaluative research on the optimization and relevance of allergy clinical offer in the a public healthcare context.  

    Dr Bégin is cochairing the redaction first Canadian clinical practice guidelines on oral immunotherapy in collaboration with the Canadian Society of Allergy and Clinical Immunology (CSACI) and the Institut national d’excellence en santé et services sociaux (INESSS). He is also co-chair of research at the Canadian Allergy, Asthma and Immunology Foundation (CAAIF).

    Awards and Distinctions

    • Innovation in Health Award, CHU Sainte-Justine, 2019
    • Dr Milton Gold Memorial Lectureship Award, Allergy, Asthma and Immunology Society of Ontario, 2018
    • Early Career Award, Canadian Society of Allergy and Clinical Immunology, 2017
    • Best Clinical Research Site of 2017 Award, INC Research, 2017
    • Emerging Clinician-Scientist Fellowship Award, AllerGEN Network of Centers of Excellence, 2013

    Major Financing

    • Canadian Institutes of Health Research, Project Ggrant Prgram
    • Fonds de recherche du Québec - Santé
    • Canadian Allergy, Asthma and Immunology Foundation (CAAIF)
    • Special funds from Quebec’s Ministry of Health and Social Services


    • Cercle d’investigations cliniques et biologiques en allergologie alimentaire (CICBAA) Annual Conference, Bruxelle, January 2020
    • Canadian Society of Allergy and Clinical Immunology (CSACI) Annual Conference, Montreal, 2019
    • European Academy of Allergy and Clinical Immunology (EAACI) Annual Conference, Lisbon, 2019
    • Bram Rose Annual Conference, Quebec Allergist and Immunologist Association, Quebec city, 2018



    1. Picard M, Robitaille G, Karam F, Daigle JM, Bédard F, Biron E, Tardif MR, Lacombe-Barrios J, Bégin P. Cross-reactivity to cephalosporins and carbapenems in penicillin-allergic patients: Two systematic reviews and meta-analyses. J Allergy Clin Immunol pract. Accepted may 2019.
    2. Langlois A, Graham F, Bégin P.  Epicutaneous immunotherapy for the treatment of peanut allergy. Expert Rev Clin Immunol. 2019, accepted march 2019.
    3. Fleischer DM, Greenhawt M, Sussman G, Bégin P, et al. Effect of Epicutaneous Immunotherapy Vs Placebo on Reaction to Peanut Protein Ingestion Among Children with Peanut Allergy: The PEPITES Randomized Clinical Trial. JAMA. ePub feb 2019.
    4. Paradis C, Cadeux-Dion M, Meloche C, Gravel M, Paradis J, Des Roches A, Leclerc G, Cossette P, Bégin P. TREX-1 related disease associated with the presence of cryofibrinogenemia. J Clin Immunol. 2019. 39(1):118-125.
    5. Labrosse R, Graham F, Des Roches A, Bégin P. Use of omalizumab with food oral immunotherapy. Arch Immunol Ther Exp. 2017; 65(3):189-199. [Review]
    6. Bégin P, Filion CA, Graham F, Paradis L, Lacombe J, Paradis J, Des Roches A. Consultation with registered dietitian to prevent accidental reactions to food: insight from an egg allergy influenza vaccination cohort. Eur J Clin Nutr. 2017; 71(2):287-289. 
    7. Bégin P, Graham F, Killer K, Paradis J, Paradis L, Des Roches A. Peanut introduction in younger siblings of children with peanut allergy: a prospective, double-blinded assessement of risk, of diagnostic tests and an analysis of patient preferences. Allergy. 2016; 71(12):1762-1771.
    8. Bégin P, Schulze J, Baron U, Olek S, Passerini L, Bauer RN, Baccheta R, Nadeau KC. Human in vitro induced T regulatory and memory T cells share common demethylation of specific FOXP3 promoter region. Clin Transl Allergy. 2015; 5:35.
    9. Bégin P, Nadeau KC. Changes in Peanut-Specific Clonotype with Oral Immunotherapy. J Allergy Clin Immunol. 2015; 135(6):1636-8.
    10. Bégin P, Dominguez T, Wilson SP, Bacal L,  Mehrotra A, Kausch B, Trela T, Hoyte E, O’Riordan G, Seki S, Blakemore A, Woch M, Hamilton R, Nadeau KC. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using omalizumab. Allergy Asthma Clin Immunol. 2014; 10(1):7.
    11. Bégin P, Wintheroth L, Dominguez T, Wilson SP, Bacal L,  Mehrotra A, Kausch B, Trela T, Hoyte E, O’Riordan G, Seki S, Blakemore A, Woch M, Hamilton R, Nadeau KC. Safety and feasibility of oral immunotherapy to multiple allergens for food allergy. Allergy Asthma Clin Immunol. 2014; 10(1):1.

Grow Beyond our wildest dreams

With the support of donors like you, at the heart of the Grow Beyond campaign, we are leading healthcare teams towards the opportunities offered by science and new technologies, so that every child, no matter where in Quebec, has access to the unique expertise and know-how of CHU Sainte-Justine. Together, let's join forces for their future.

Grow Beyond with us.

Contact Us

514 345-4931


© 2006-2014 CHU Sainte-Justine.
All rights reserved. 
Terms of Use,  Confidentiality,  Security


All information contained within the CHU Sainte-Justine site should not be used as a substitute for the advice of a duly qualified and authorized medical practitioner or any other health professional. The information provided on this site is intended for educational and informational purposes only.

Consult your physician if you feel ill or call 911 for any medical emergency.

CHU Sainte-Justine